UNSPSC 51384702: Emorfazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H17N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V93U9DH62C, chemically known as 3(2h)-pyridazinone, 4-ethoxy-2-methyl-5-morpholino- but generally known as emorfazone, which bears US NIH Compound Identifier 3221. European Medicines Agency schedules Emorfazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06511MIG. The term EMORFAZONE is an International Non-Proprietary Name.

UNSPSC 51384702 Emorfazone is a Commodity code under which state and local governments procure pharmaceutical products and medical supplies related to opioid management and drug disposal. The recent solicitation activity shows purchasing of naloxone (a lifesaving opioid antagonist) and safe drug deactivation systems to support community health and harm-reduction initiatives. These are specialized medical countermeasures deployed by public health authorities, typically in quarterly cycles with fixed contract terms and renewal options.

Seminole County, Florida issued an IFB (Invitation for Bid) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement required electronic bid submission through the county's e-Procurement Portal, unit pricing for each line item, E-Verify compliance, drug-free workplace certification, and standard commercial insurance coverage (workers' compensation, general liability, professional liability). The contract structure included a two-year initial term with a one-year renewal option and a three-month probationary period allowing termination at will. The solicitation noted potential FEMA funding with associated federal compliance requirements under the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations were listed. The response deadline was July 26, 2023, at 2:00 pm.